We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I agree capacity needs to ramp up GP. It’s obvious to all that testing is the way forward and will become the new norm...however we really need to see some news on orders? There is so little news from CK that it makes me think it’s a deliberate but why would the other tests we manufacture fall under this blackout?
Just read the whole Tony Blair article. It is crystal clear to me that testing is the only way the economy can survive is to test test test.
I’m increasing my holding by 100% based on our capacity to manufacture all tests increasing to 2 million a week. I can see that coming before Xmas. So can the market.
Excellent read. Brilliant find Bermuda shorts. I hope it gets some traction. Bit of a worry that it says Mologic's antibody test has been blocked. I guess they are prioritising the RTC. Confirmed that ODX are getting the order for half a million a week. Looks like Mologic are going international with orders on the way. Good that the RTC and our Mologic partnership have been specifically recognised.
Safy we have talked about the Mologic antigen saliva test a lot. We have a few trolls who affect to misunderstand and/or confuse what we have. It's useful to read the investors presentation. It has everything in there.
The poc, lateral flow, non instrument is saliva based. These are similar to hiv, visitect in method and being developed now
Safy
My understanding is that they are developing both. Either linked together or separately
I.e either one test suitable for swob/saliva or individually. Maybe one for the company to clarify
I have emailed ODX for clarification. If it’s Saliva then that is significant news. Something that has been overlooked by the bb.
The timescales have been brought forward from last update.
Both mologic antigen saliva
Upomega / unvrkw
Lol which one? Saliva or blood?
Mologic
Mologic currently has four serology tests available.
ELISA test for IgG only: This test is available now, and production could be scaled to 500,000 tests per week. As it stands, there is no sign of the test being validated by Public Health England (PHE), but there have been positive conversations with PHE Colindale.
Professional RDT for IgG, IgM and IgA: These diagnostic devices would identify a full range of antibodies. Forms have been submitted to the New Test Approvals Group (NTAG) but no reply has been received. The test is being provided on a not-for-profit basis with a number of international partners and there are proposals for 200 million-plus capacity units here and in Africa.
Self-test for IgG only: This home-testing kit could be used by a layperson to identify if they had IgG antibodies and therefore had some evidence of past infection. To date, the regulatory pathway has been blocked by MHRA.
Laminated test in IgG only or G, M and A: The laminate tests provide a quick result and show if a patient has had exposure to Covid-19. Plasma from a sample soaks along a laminate of what is essentially paper, encountering a zone that has known coronavirus antigens. If the plasma has antibodies to the coronavirus proteins, those will bind to the test antigens and carry them along up the strip giving a result. These tests are being developed for both professional use and self-testing. They are being distributed internationally.
What’s in the pipeline?
In the medium-term, Mologic is developing T-cell and Memory B-cell marker variants of the antibody test to confirm immune memory. These are critical to the debate around immunity.
The pre-mentioned antigen tests are subject to regulatory hold-up but could be online very quickly. The company is also looking to develop peptide antigen driven tests (for lower cross-reactivity), similar to that of the HIV rapid tests.
The antigen tests being developed by Mologic are saliva based.
As far as I can see the material agreement with moligic covers blood salava and swob.
The last placing was to cover expansion to 2 million tests per week. Any further expansion should be funded by sales.
Antibody testing is potentially an important part of the puzzle. Further evidence is needed on the level of immunity conferred by infection, but we believe it does confer a level of protection from reinfection. In addition, we are increasingly seeing evidence of long-term health implications in patients who have had Covid-19. Without a broader understanding of who has had the virus, we will not be able to understand this issue more fully. Large-scale rapid antibody testing will help build up a picture of who has had the virus, providing important information.
Antibody testing to support PCR testing. Where employers are running larger scale antigen testing (eg, to avoid shutting down operations), some are also offering antibody testing so that they can avoid regular PCR testing for a three-month period.
Antibody testing provided as an employee benefit. Some employers, particularly in financial and legal services, are providing voluntary antibody tests to individuals to enable them to find out whether they have had coronavirus earlier in the year.
In recent months there has been increased interest in antigen testing. However, to date, we haven’t seen any evidence of mass antigen testing by employers to manage core business activities. This is primarily because only lab-based swab tests are currently available. The key game-changer in the way employers will use testing will be the commercial availability of simple self-sampling (nasal or oral swabs) and rapid turnaround of results using alternative test modalities to PCR.
Widespread availability of instant-result antibody tests (eg, the AbC lateral flow test) may also enable employers to monitor whole-workforce immunity status over time.
From the link....Isn’t that our test?
Can someone please confirm that the Mologic Elisa test works on Saliva and NOT swab. According to the post above it says Saliva but I’m guessing this is a typo.
If it is Saliva this is HUGE news.
Interesting post bermudashorts. I just hope that any future expansion will now be funded by grants and not another placing.
The following report was published yesterday and may already have been mentioned here but there are too many posts to scroll back and check so if it's old news then please ignore. It makes interesting reading and Omega gets a mention:-
'Omega Diagnostics
Through its partnership with Mologic, the company is developing ELISA and lateral flow antigen tests that will use saliva as the sample type. These tests will offer a quicker time to result and an easier sample-collection method than current testing methods (particularly swab tests). The expectation is that the ELISA antigen test will be available by the end of September and the lateral flow test by the end of October or November.
Omega recently informed us that it is currently working towards manufacturing capacity for rapid tests of 0.5 million per week. The company believes it could double this quite quickly with government support – particularly in terms of financial and logistical support.'
https://institute.global/policy/science-fiction-science-and-fact-realistic-route-mass-testing